Studies have shown that active fund managers routinely underperform the S&P500 index*​

LENZ Therapeutics, Inc. (NASDAQ: LENZ)

LENZ Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
218.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
351.50%

LENZ Stock Analysis

LENZ PE Ratio:

LENZ PEG Ratio: Not Available

LENZ Forward EPS Growth (12 month): 0.00%

LENZ PS Ratio: 10.5

LENZ PSG Ratio:

LENZ Forward Revenue Growth (12 month): 238.90%

LENZ Articles

No data was found